Log In
Print
BCIQ
Print
Print this Print this
 

Amitiza, lubiprostone (SPI-0211)

  Manage Alerts
Collapse Summary General Information
Company Sucampo Pharmaceuticals Inc.
DescriptionFunctional fatty acid chloride channel activator
Molecular Target Chloride channel 2 (CLCN2) (ClC-2) ; Potassium channel KCa1.1 (KCNMA1) (SLO)
Mechanism of ActionCl channel activator
Therapeutic ModalityMacromolecule: Fatty acid/lipid

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

0

$10.0M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today